Clinical Trial Update: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL [Phase 1, Phase 2]

View source ↗

Summary

The QUILT-3.052 trial evaluating the NANT Non-Hodgkin Lymphoma Vaccine in relapsed CD20-positive NHL has been withdrawn (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• NANT Non-Hodgkin Lymphoma Vaccine

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN